Aravive ARAV Stock
Aravive Price Chart
Aravive ARAV Financial and Trading Overview
| Aravive stock price | 0.04 USD |
| Previous Close | 1.58 USD |
| Open | 1.58 USD |
| Bid | 0 USD x 1100 |
| Ask | 0 USD x 1000 |
| Day's Range | 1.53 - 1.6 USD |
| 52 Week Range | 0.58 - 2.46 USD |
| Volume | 265.17K USD |
| Avg. Volume | 289.91K USD |
| Market Cap | 93.96M USD |
| Beta (5Y Monthly) | 2.35 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13 USD |
ARAV Valuation Measures
| Enterprise Value | 61.55M USD |
| Trailing P/E | N/A |
| Forward P/E | -1.256 |
| PEG Ratio (5 yr expected) | -0.01 |
| Price/Sales (ttm) | 9.85282 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 6.454 |
| Enterprise Value/EBITDA | -0.845 |
Trading Information
Aravive Stock Price History
| Beta (5Y Monthly) | 2.35 |
| 52-Week Change | 68.45% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 2.46 USD |
| 52 Week Low | 0.58 USD |
| 50-Day Moving Average | 1.66 USD |
| 200-Day Moving Average | 1.52 USD |
ARAV Share Statistics
| Avg. Volume (3 month) | 289.91K USD |
| Avg. Daily Volume (10-Days) | 352.93K USD |
| Shares Outstanding | 59.84M |
| Float | 18.77M |
| Short Ratio | 23.71 |
| % Held by Insiders | 47.55% |
| % Held by Institutions | 25.79% |
| Shares Short | 5.09M |
| Short % of Float | 97.87% |
| Short % of Shares Outstanding | 8.50% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:6 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -773.40% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -78.85% |
| Return on Equity (ttm) | -38510.54% |
Income Statement
| Revenue (ttm) | 9.54M USD |
| Revenue Per Share (ttm) | 0.19 USD |
| Quarterly Revenue Growth (yoy) | 36.50% |
| Gross Profit (ttm) | -57801000 USD |
| EBITDA | -72873000 USD |
| Net Income Avi to Common (ttm) | -113221000 USD |
| Diluted EPS (ttm) | -2.14 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 35.92M USD |
| Total Cash Per Share (mrq) | 0.6 USD |
| Total Debt (mrq) | 3.52M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 1.935 |
| Book Value Per Share (mrq) | -0.645 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -69941000 USD |
| Levered Free Cash Flow (ttm) | -41393000 USD |
Profile of Aravive
| Country | United States |
| State | TX |
| City | Houston |
| Address | River Oaks Tower |
| ZIP | 77098 |
| Phone | 936 355 1910 |
| Website | https://aravive.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 23 |
Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.
Q&A For Aravive Stock
What is a current ARAV stock price?
Aravive ARAV stock price today per share is 0.04 USD.
How to purchase Aravive stock?
You can buy ARAV shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Aravive?
The stock symbol or ticker of Aravive is ARAV.
Which industry does the Aravive company belong to?
The Aravive industry is Biotechnology.
How many shares does Aravive have in circulation?
The max supply of Aravive shares is 73.56M.
What is Aravive Price to Earnings Ratio (PE Ratio)?
Aravive PE Ratio is 0.00000000 now.
What was Aravive earnings per share over the trailing 12 months (TTM)?
Aravive EPS is 0 USD over the trailing 12 months.
Which sector does the Aravive company belong to?
The Aravive sector is Healthcare.
Aravive ARAV included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}